Morioka Kazuhito, Tanikawa Chizu, Ochi Kensuke, Daigo Yataro, Katagiri Toyomasa, Kawano Hirotaka, Kawaguchi Hiroshi, Myoui Akira, Yoshikawa Hideki, Naka Norifumi, Araki Nobuto, Kudawara Ikuo, Ieguchi Makoto, Nakamura Kozo, Nakamura Yusuke, Matsuda Koichi
Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Cancer Sci. 2009 Jul;100(7):1227-33. doi: 10.1111/j.1349-7006.2009.01165.x. Epub 2009 Apr 15.
Osteosarcoma is the most prevalent bone malignant tumor in children and adolescents, and displays heterogeneous histology and high propensity for distant metastasis. Although adjuvant chemotherapy remarkably improved treatment outcome over the past few decades, prognosis for osteosarcoma patients with pulmonary metastasis is still unsatisfactory. To identify novel therapeutic targets for osteosarcoma, we investigated the gene expression profile of osteosarcomas by cDNA microarray analysis and found transactivation of receptor tyrosine kinase-like orphan receptor 2 (ROR2) expression in the majority of osteosarcoma samples. Treatment of osteosarcoma cell lines with siRNA against ROR2 significantly inhibited cell proliferation and migration. We also identified wingless-type MMTV integration site family, member 5B (WNT5B) as a putative ROR2 ligand and that the physiological interaction of WNT5B and ROR2 could enhance cell migration, indicating the possible roles of ROR2 and WNT5B in the metastatic property of osteosarcoma cells. Taken together, our findings revealed that the WNT5B/ROR2 signaling pathway is a promising therapeutic target for osteosarcoma.
骨肉瘤是儿童和青少年中最常见的骨恶性肿瘤,具有异质性组织学特征,且远处转移倾向高。尽管在过去几十年中辅助化疗显著改善了治疗效果,但肺转移骨肉瘤患者的预后仍不尽人意。为了确定骨肉瘤的新治疗靶点,我们通过cDNA微阵列分析研究了骨肉瘤的基因表达谱,发现大多数骨肉瘤样本中受体酪氨酸激酶样孤儿受体2(ROR2)表达呈反式激活。用针对ROR2的小干扰RNA(siRNA)处理骨肉瘤细胞系可显著抑制细胞增殖和迁移。我们还确定无翅型MMTV整合位点家族成员5B(WNT5B)为假定的ROR2配体,且WNT5B与ROR2的生理相互作用可增强细胞迁移,这表明ROR2和WNT5B在骨肉瘤细胞转移特性中可能发挥作用。综上所述,我们的研究结果表明WNT5B/ROR2信号通路是骨肉瘤一个有前景的治疗靶点。